An Open Label Multi-part First-in-human Study of Oral LMI070 in Infants With Type 1 Spinal Muscular Atrophy
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 30 Sep 2017
At a glance
- Drugs Branaplam (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Novartis
- 03 Aug 2017 Planned number of patients changed from 42 to 44.
- 24 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 30 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Aug 2017.